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Abstract 
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial 
fibrillation (AF) and management of venous thromboembolism (VTE), resulting in a 
reduction in thrombotic complications and mortality. Benefit of vitamin K antagonists 
(VKAs) in such patients have been unambiguously confirmed, but VKA use is 
complicated by need for regular monitoring of the international normalized ratio and 
multiple drug and food interactions.  
 
Dabigatran is an oral direct thrombin inhibitor that can be used with fixed doses, 
without the need for routine anticoagulation laboratory monitoring and the advantage 
of few drug or diet interactions. Dabigatran is effective for stroke and systemic 
thromboembolism in AF and for the prophylaxis and treatment of VTE. The drug has 
a good safety profile and consistently shows a reduction in intracranial haemorrhage 
risk compared to warfarin. A specific reversal agent for dabigatran has been approved 
by FDA and EU. This review provides a summary of publications assessing clinical 
utility of dabigatran for different indications. 
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Introduction 
 
Introduction of oral anticoagulation as a preferable choice for stroke prevention in 
non-valvular atrial fibrillation (AF) has dramatically changed outlook in this common 
condition.[1] In the Stroke Prevention in Atrial Fibrillation Study (SPAF) 
randomized, double blind trial warfarin reduced the risk of ischemic stroke and 
systemic embolism by two thirds compared to placebo in patients deemed eligible for 
warfarin treatment.[2] The meta-analysis of the clinical trials on the vitamin K 
antagonists (VKA) compared to placebo has demonstrated a 64% relative risk 
reduction in stroke or systemic embolism and rates of all-cause mortality were 26% 
lower in the warfarin group.[3] There was also a 39% relative risk reduction in all 
strokes with VKA compared to aspirin.[3] Consequently net benefits of VKA in AF 
have been unambiguously confirmed and these agents became the standard for 
SPAF.[4, 5]  
 
Warfarin and other VKAs have multiple pharmacokinetic and pharmacodynamics 
limitations including multiple food and drug interactions and need for meticulous 
laboratory monitoring. These limitations together with fear of bleeding complications 
contributed to large-scale underutilization of VKAs, particularly in older people.[6] In 
fact, age of more than 75 years was considered a criterion for warfarin ineligibility in 
the SPAF trial aiming to avoid a population with perceived high risk of 
hemorrhage.[2] Limitations of the VKA based oral anticoagulant (OAC) prompted 
development of specific inhibitors of the key components of the coagulation cascade 
preferably acting independently of cofactors. Thrombin has become a natural 
anticoagulation target of choice being the end-cascade coagulation factor for both 
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 4 
intrinsic and extrinsic coagulation pathways.[7] 
 
Dabigatran etexilate (Boehringer Ingelheim) is a direct, reversible non-peptide 
inhibitor of both free and clot-bound thrombin (Table 1).[8] Dabigatran etexilate is a 
prodrug, which differs from dabigatran by an ethyl group at the carboxylic acid and a 
hexyloxycarbonyl side chain at the amidine, which allows better (approximately 
6.5%) bioavailability on oral intake.[9, 10] The formation of dabigatran occurs by 
esterase-catalyzed hydrolysis in the plasma and liver. After oral intake the plasma 
levels of dabigatran peak within 1-2 hours. Upon regular use dabigatran has a half-life 
of 14-17 hours, and is used twice daily to maintain plasma concentrations and 
anticoagulant properties.[11-13] About 80% of dabigatran is excreted unchanged by 
the kidneys and 20% of the drug undergoes biliary conjugation and excretion.[13] As 
a result renal dysfunction delays dabigatran elimination and it is contraindicated in 
patients with severe renal failure. Dabigatran has low propensity to drug-drug 
interactions as its metabolism does not involve cytochrome P450 enzymes and it has 
low plasma protein binding of only 35%.[11, 14, 15] No dabigatran dose modification 
is needed for concomitant use with amiodarone and quinidine. In contrast to 
ximelagatran, dabigatran does not lead to hepatotoxicity. Dabigatran etexilate has no 
known interactions with food.[16] 
 
A few drug-drug interactions still need to be considered when dabigatran is 
prescribed. The absorption of dabigatran etexilate in upper gastrointestinal system is 
affected by acidity of the content. Tartaric acid-containing capsules are used to 
optimize absorption of the drug and only intact capsules must be used.[17] 
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Dabigatran etexilate is a substrate of P-glycoprotein and the drug’s concentration may 
vary when it is used simultaneously with potent P-glycoprotein inhibitors or inducers. 
For example, verapamil, a P-glycoprotein inhibitor may increase plasma 
concentrations of dabigatran, and dronedarone, systemic ketoconazole, cyclosporine 
and itraconazole are contraindicated in the European Union (EU) summary of the 
product characteristics. [18] Other examples of potent P-glycoprotein inhibitors are 
other azole-based antimycotics, various immunosuppressants, and human 
immunodeficiency virus protease inhibitors—their combination with dabigatran 
should be used with caution. Dabigatran should not be used with potent P-
glycoprotein inducers such as rifampicin.  
 
Stroke prevention in atrial fibrillation 
 
The efficacy and safety of dabigatran for the prevention of stroke and systemic 
embolism in patients with non-valvular AF was assessed in the controlled, non-
inferiority Randomized Evaluation of Long-term anticoagulant therapy (RE-LY) 
trial.[19] In this trial 18113 AF patients from 44 countries were randomized to receive 
110 mg dabigatran twice daily (bid), 150 mg dabigatran bid (the two dabigatran doses 
were blinded) or open-labeled warfarin (dose adjusted for target international 
normalized ratio [INR] 2-3). The principle inclusion criteria were documented AF 
with one of the following: previous stroke or transient ischemic attack, a left 
ventricular ejection fraction ≤40%, heart failure symptoms compatible with New 
York Heart Association (NYHA) class II or higher within 6 months before screening, 
and an age of ≥75 years or a combination of age of 65-74 years with diabetes mellitus, 
hypertension, or coronary artery disease. The key exclusion criteria were severe 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 6 
cardiac valve disease, recent stroke, increased bleeding risk, creatinine clearance <30 
ml/min, active liver disease, and pregnancy. The median follow up was 2-years and 
all analyses were based on the intention-to-treat principle.  
 
The primary outcome measure of stroke (including hemorrhagic stroke) and systemic 
embolism was significantly reduced with 150 mg bid dabigatran dose (relative risk 
0.65; p <0.001), which paralleled reduction in hemorrhagic stroke from 0.38% per 
year in the warfarin group to 0.10% per year in the dabigatran 150 mg bid group (p 
<0.001).[20] No difference in the major bleeding risk was evident with this dose. The 
lower, 110 mg bid dose was associated with stroke risks similar to those on warfarin, 
but there were significantly less major bleeding events (20% relative risk reduction, 
p=0.003). The mortality rate was 3.75% with 110 mg of dabigatran and with 150 mg 
of dabigatran was 3.64% as compared with 4.13% in the warfarin group (p=0.13 for 
110 mg dose and p=0.051 for 150 mg dose).[19] The favorable effects of dabigatran 
were evident despite well maintained time in therapeutic range in the warfarin group 
(i.e., mean of 64%). 
 
Overall dabigatran was well tolerated with no evidence of liver dysfunction. However 
dyspepsia was about twice more common with both dabigatran doses compared to 
warfarin. A numerical but non-significant increase in myocardial infarction incidence 
was observed in the dabigatran groups (0.8%) compared to warfarin treated patients 
(0.6%), with 110 mg dabigatran dose (p=0.09) and with 150 mg dose (p=0.12). [21] 
However, treatment with 150 mg bid dabigatran dose showed significant reduction in 
vascular death compared to warfarin (relative risk 0.85, 95% confidence interval [CI] 
0.72-0.99, p=0.021) with similar numerical trend seen for the 110 bid dose. 
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RELY-ABLE  
Upon completion of the RE-LY trial, 48% of its participants receiving dabigatran 
were enrolled into the follow-up Long-term Multicenter Extension of Dabigatran 
Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial. After a median 
follow-up of 2.3 years there was no significant difference between the two dabigatran 
doses in rates of stroke or systemic embolism, death and hemorrhagic stroke. 
However the annual rates of major hemorrhage were higher with dabigatran 150 mg 
than 110 mg (3.74% vs 2.99%, hazard ratio [HR] 1.26, 95% CI 1.04-1.53).[22] 
 
EU label analysis 
Dabigatran has been approved by all major regulatory bodies, such US Food and 
Drug Administration (FDA) and the European Medicines Evaluation Agency 
(EMEA) for the prevention of stroke and systemic embolism in patients with non-
valvular AF. However, although the recommended treatment regime aimed to 
resemble the RE-LY trial protocol it cannot be considered equivalent to the trial 
protocol, with the observational studies lacking randomization by their nature. The 
EU label recommends the use of 150 mg bid dabigatran dose in patients with AF who 
are less 80 years old and do not have an increased risk for bleeding (e.g., HAS-BLED 
score <3) and not receiving verapamil. All other AF patients eligible for oral 
anticoagulation are recommended to receive 110 mg bid dose. A post-hoc analysis of 
over 12000 participants of the RE-LY trial showed that when prescribed based on the 
EU recommendations dabigatran significantly reduced rates of stroke and systemic 
embolism (HR 0.74, 95% CI 0.60-0.91), hemorrhagic stroke (HR 0.22, 95% CI 95% 
CI 0.11-
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CI 0.68-0.95).[23] Also, dabigatran showed excellent safety profile with lower risk of 
major bleedings (HR 0.85, 95% CI 0.73-0.98), life-threatening bleedings (HR 0.72, 
95% CI 0.58-0.91), intracranial hemorrhage (HR 0.28, 95% CI 0.17-0.45), and any 
bleeding (HR 0.86, 95% CI 0.81- ests that when used 
in accordance with the EU label dabigatran has superior efficacy and safety compared 
to warfarin. 
 
Renal function 
Renal impairment increases the risk of stroke and bleeding in AF patients. As 
dabigatran is largely eliminated by renal excretion severe kidney dysfunction may 
increase the drug’s plasma concentrations and most regulatory authorities do not 
recommend dabigatran in people with creatinine clearance <30 ml/min. The ESC 
guidelines on management of AF recommend annual assessment of renal function in 
individuals with baseline creatinine clearance 50–79 ml/min with more frequent 
assessment (2–3 times per year) in those with creatinine clearance 30–49 ml/min.[4, 
5] If the creatinine clearance falls below 30 ml/min warfarin should be started instead 
of dabigatran. The approach is also applicable when dabigatran is used for other 
indications, for example VTE. A different approach is used in the US where FDA 
approved a lower 75 mg bid dose of dabigatran in patients with creatinine clearance 
15-30 ml/min. This approach is based on pharmacokinetic modelling and has not been 
tested in a randomised clinical trial. In the RE-LY trial impairment of renal function 
was associated with higher rates of stroke and systemic embolism, major bleeding, 
and all-cause mortality (Figures 1-4) in all treatment arms. However, the efficacy of 
the both doses of dabigatran remained consistent through out the whole ranges of 
renal function accepted for participation in the trial.[24]  
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Elderly patients 
Older patients with AF are less likely to receive oral anticoagulation despite evidence 
that benefits of oral anticoagulation outweigh any age-related increase in risk of 
bleeding.  Simplicity of dabigatran administration brings clear benefits for 
management of older people and both the RE-LY and RELY-ABLE trials had no 
upper age restrictions. There was a significant treatment-by-age interaction regarding 
the risk of bleeding in the RE-LY trial.[25] Compared to warfarin, in patients younger 
than 75 years dabigatran was associated with almost 40% lower relative risk of major 
bleeding with the 110 mg bid dose and 30% lower relative risk of the major bleeding 
with the 150 mg bid dose (p<0.001 for both). In subjects aged 75 years or older the 
110 mg dose was related to a similar risk of major bleeding to warfarin whilst the 150 
mg dose showed a trend towards higher risk of major bleeds (5.10% vs. 4.37% with 
warfarin, p=0.07). The interactions were observed for extracranial but not intracranial 
bleeding events.  
 
CHA2DS2-VASc score 
In the RE-LY trial, higher CHADS2 scores in AF patients were associated with 
increased risks for death, stroke or systemic embolism, bleeding in both the warfarin 
and dabigatran groups.[26] The clinical benefits of dabigatran established in the trial 
were consistent throughout the whole range of the CHADS2 scores tested. A modeling 
analysis based on the EuroHeart Survey on AF and extrapolation of outcomes of the 
RE-LY trial suggested that utilization of dabigatran instead of warfarin in the 
European population with AF and CHA2DS2-VASc score ≥2 would annually prevent 
43,235 deaths and major cardiovascular events with the 150 mg bid dose and 27,272 
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of such events with the 110 mg bid dose.[27] 
 
Primary thromboembolism prevention in venous thromboembolism 
VTE, that includes deep vein thrombosis (DVT) and pulmonary embolism (PE) is a 
significant healthcare problem associated with substantial morbidity and 
mortality.[28-30] A large study reported 11% 30-day and 23% 1-year case mortality 
in VTE.[31] Unprovoked VTE has a strong propensity for recurrence, which occurs in 
1 in 10 patients within 1 year and in every third patient within 3 years.[32] VTE is 
associated with high healthcare costs to cover high expenses of hospitalization, 
professional costs, and outpatient procedures.[33]  
 
The effectiveness and safety of dabigatran for primary venous thromboembolism 
(VTE) prevention in patients after major joint surgery, was established in randomized, 
double-blind, placebo-controlled trials (Table 2). In the RE-MODEL trial dabigatran 
150 mg once daily or 220 mg once daily, starting with a half-dose 1–4 hours after 
total knee replacement was compared to enoxaparin 40 mg once daily starting the 
evening before surgery with the treatment continued for 6-10 days.[34] Both 
dabigatran doses were non-inferior to enoxaparin for prevention of the primary 
efficacy outcome of a composite of total VTE and mortality during the treatment 
(occurred in 37.7% of participants in the enoxaparin group, 36.4% of the 220 mg 
dabigatran group and 40.5% of the 150 mg dabigatran group). There was no 
difference in incidence of major hemorrhage between the three groups (1.3%, 1.5% 
and 1.3%, respectively). 
 
In the RE-NOVATE trial dabigatran was compared with warfarin in patients 
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undergoing total hip replacement with treatment continued for 28–35 days.[35] Both 
150 mg and 220 mg dabigatran doses were not inferior to warfarin, for prevention of 
VTE and all-cause mortality (6.7% in the enoxaparin group, 6.0% in the dabigatran 
220 mg group and 8.6% in the 150 mg group) with no difference seen in major 
bleeding rates. In the phase III RE-NOVATE II trial of thromboprophylaxis for total 
hip replacement the primary efficacy outcome of total VTE or all-cause death was 
recorded in 7.7% of the dabigatran group versus 8.8% of the enoxaparin, confirming 
non-inferiority of dabigatran.[36] 
 
The success of dabigatran in VTE prevention in major joint surgery was not repeated 
in the double-blind, randomized RE-MOBILIZE trial when the drug was tested 
against the North American enoxaparin regimen (30 mg bid instead of 40 mg once 
daily).[37] In this trial both dabigatran doses had lower efficacy compared to 
enoxaparin (VTE rates of 31% for 220 mg dabigatran, 34% for 150 mg dabigatran vs. 
25% for enoxaparin). Major bleeding rates were similar in the three groups. 
 
Management of venous thromboembolism 
 
Oral and parenteral anticoagulation has been widely used to prevent VTE 
recurrence.[38] The commonly used treatments included heparin-based 
anticoagulants, such as unfractionated heparin and low-molecular-weight heparins, 
fondaparinux, and VKAs. Dabigatran brings significant advantages compared to those 
treatments being administered orally with predictable anticoagulation response and no 
need for laboratory monitoring of anticoagulation. Costs of dabigatran can be small 
compared to overall costs of management of DVT and its complications, if hospital 
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admissions are required. 
 
RE-COVER I and RE-COVER II  
In the double-blind, placebo-controlled noninferiority RE-COVER trial 2539 patients 
with acute VTE initially treated by parenteral anticoagulation (typically by 
intravenous heparin or subcutaneous low molecular weight heparin for a median of 9 
days were randomized for 6 month treatment with oral dabigatran 150 mg bid or 
warfarin (INR 2.0-3.0).[39] The primary end point was a combination of symptomatic 
VTE or death associated with VTE within 6 months from randomization (Table 3).  
 
The study results underwent a modified intention-to-treat analysis with patients who 
did not receive any study drug being excluded. In the warfarin group the INR was 
within the therapeutic range 60% of the time. Recurrent VTE occurred in 2.4% of 
patients treated with dabigatran and 2.1% of patients receiving warfarin (HR 1.10, 
95% CI 0.65-1.84, p<0.001 for the non-inferiority test). Major bleeding occurred in 
1.6% of patients receiving dabigatran and 1.9% of those on warfarin (HR 0.82, 95% 
CI 0.45-1.48). Any bleeding was significantly less common in the dabigatran group 
(16.1%) than in the warfarin group (21.9%, HR 0.71, 95% CI 0.59-0.85). There was 
no significant difference in rates of deaths, acute coronary syndromes or increase in 
liver enzymes between the treatment groups. Treatment discontinuation rates were 
9.0% with dabigatran and in 6.8% with warfarin.[39] Results of the RE-COVER trial 
were consequently confirmed by the RE-COVER II study, which had a similar design 
and recruited 2589 patients.[40] Pooled analysis of the RE-COVER and RE-COVER 
II studies confirmed non-inferiority of dabigatran for prevention of VTE recurrence 
(HR 1.09, 95% CI 0.76-1.57), for risk of major bleeding (HR 0.73, 95% CI 0.48-
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1.11). Analysis of the double-dummy phase of the trial, which included patients who 
actually received dabigatran showed significantly lower rates of major bleeding in the 
dabigatran group (HR 0.60, 95% CI 0.36–0.99). The analysis also showed reduction 
in risk for any bleeding in patients treated by dabigatran (HR 0.70, 95% CI 0.61-0.79 
for the study overall and HR 0.67, 95% CI 0.59–0.77 for the double dummy 
phase).[40] Although the frequency of any gastrointestinal bleeds in the RE-COVER 
program was numerically higher with dabigatran than with warfarin, dabigatran was 
associated with lower rate of major gastrointestinal bleeds.[41] In the dabigatran 
group no increase in bleeding risk was observed in patients who were treated with 
nonsteroidal anti-inflammatory drugs with a half-life <12 hours or low-dose 
aspirin.[42] 
 
Similarly to the AF RE-LY trial, patients with creatinine clearance <30 ml per minute 
were excluded from the RE-COVER and RE-COVER II studies. Given the 
predominantly renal route of dabigatran elimination a prespecified subgroup analysis 
of pooled data from RE-COVER and RE-COVER II was performed to establish the 
efficacy and safety of dabigatran in relation to renal function. The analysis did not 
find any significant treatment interaction by renal function. Dabigatran efficacy was 
preserved and superiority regarding any bleeding events maintained throughout the 
whole range of renal function eligible for inclusion into the study.[43] Dabigatran was 
similarly effective to warfarin across all age groups.[44, 45] Although rates of 
bleeding events were higher in older patients overall bleeding was less frequent in 
those receiving dabigatran compared to patients treated with warfarin irrespectively of 
age. These studies indicate no need for dabigatran dose adjustment of in patients with 
mild or moderate kidney dysfunction or in older subjects. However the European 
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Medical Agency has still advised that the lower dose of 110 mg bid should be used in 
patients aged 80 and above.[18] 
 
In acute VTE management, dabigatran is started after an initial period of parenteral 
anticoagulation (e.g., 5 days of low molecular weight heparin in the UK or 5-10 days 
of heparin or low molecular weight heparin in the US). This differs from the approach 
used in trials of apixaban (AMPLIFY trial) and rivaroxaban (EINSTEIN-DVT study), 
which can be started from the disease onset.[46, 47] There is no direct comparison 
data on whether any one of the agents offer clinical superiority over another and all 
three agents are licensed for acute DVT. 
 
The efficacy of dabigatran is similar in patients with or without active cancer.[48, 49] 
Patients with cancer were more prone to bleeding overall, but treatment with 
dabigatran was associated with fewer major bleeding (HR 0.60, 95% CI 0.36-0.99) 
and overall bleeding (HR 0.56, 95% CI 0.45-0.71). In the RE-COVER program there 
was a significantly higher frequency of recurrent VTE or VTE-related mortality 
among patients who had active cancer, but the efficacy of dabigatran versus warfarin 
was similar irrespective of cancer status.[48, 49] In the pooled analysis of the program 
the risk of recurrence was similar in patients who presented initially with PE or DVT 
and the treatment efficacy of dabigatran was not affected by the presence of 
thrombophilia.[50, 51] 
 
RE-MEDY and RE-SONATE 
Whilst the RE-COVER program tested efficacy and safety of dabigatran during a 6-
month period of treatment, many VTE patients, particularly those with evidence of 
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thrombophilia or history of recurrent thrombosis require more prolonged 
anticoagulation.[52] The RE-COVER program was extended to establish utility of 
dabigatran for prolonged use in VTE in comparison to either warfarin (active control, 
the RE-MEDY study, n=2856) or placebo (the RE-SONATE trial, n=1343). These 
two randomized, double-blinded trials enrolled patients who had already completed at 
least 3 months of treatment for VTE.  
 
The definition of VTE and studies’ outcomes were generally similar to those in the 
RE-COVER program and its participants consequently contributed to almost 80% 
patients of the RE-MEDY study and 4.0% of subjects of the RE-SONATE study. 
Unexplained death was additionally included as part of the primary efﬁcacy outcome 
in the RE-SONATE. Also, the trial excluded patients who received thrombolytic 
therapy within 14 days prior to the recruitment, had malignancy or inferior vena cava 
ﬁlters implanted. The median treatment duration was approximately 16 months in the 
RE-MEDY trial and 4.5 months in the RE-SONATE trial. Modified intention-to-treat 
analysis was followed similar to the RE-COVER study. Bleeding events were 
included into the analysis if occurred during the period between the first dose of the 
study drug and 3 days after administration of the last dose. 
 
In the RE-MEDY study, recurrent VTE occurred in 1.8% of participant of the 
dabigatran group and 1.3% of patients in the warfarin group (HR 1.44, 95% CI 0.78-
2.64; p=0.01 for non-inferiority). Major bleeding complications occurred in 0.9% of 
patients treated by dabigatran and 1.8% of those receiving warfarin (HR 0.52, 95% CI 
0.27-1.02). Any clinically relevant bleedings were less frequent with dabigatran (HR 
0.54, 95% CI 0.41-0.71). Acute coronary syndromes were recorded slightly more 
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frequently in the dabigatran group than in the warfarin group (0.9% vs. 0.2%, 
respectively, p=0.02).[53] However, this was at least partly due to the fact that more 
patients in the dabigatran group had coronary artery disease than in the warfarin group 
(8.4% and 6.1%, respectively). In the RE-MEDY trial 18% of participants had 
features of thrombophilia with Factor V Leiden thrombophilia being the most 
common type.[54] Treatment efficacy of dabigatran as compared to warfarin was not 
significantly affected by the presence of thrombophilia. 
 
In the assessment based on the RE-MEDY trial criteria the net clinical benefit for a 
cumulative end-point of nonfatal recurrent VTE, nonfatal myocardial infarction, 
nonfatal stroke, nonfatal systemic embolism, all-cause death, and major bleeding 
events was similar between dabigatran and warfarin (HR 1.05, 95% CI 0.75-1.46). 
For the broader outcome that included any clinically relevant bleeding events the net 
clinical benefits favored dabigatran over warfarin (HR 0.73, 95% CI 0.59-0.91). 
Stratification of the net clinical benefit by the time in the therapeutic range in warfarin 
group confirmed the benefits of dabigatran treatment over warfarin despite good INR 
control.[55] 
 
In the RE-SONATE study, recurrent VTE occurred more than 10-fold less frequently 
in the dabigatran group than in the placebo group (0.4% vs. 5.6%, respectively, HR 
0.08; 95% CI 0.02-0.25; p<0.001). Major bleeding was extremely rare (in 2 patients 
in the dabigatran group and none in the placebo group). Any clinically relevant 
bleeding was more frequent in the dabigatran group (5.3% vs. 1.5%, respectively, HR 
2.92; 95% CI 1.52-5.60).[53] During 1 year of extended follow-up the primary 
efficacy outcome events occurred 55% more frequently in the placebo than in the 
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dabigatran group (10.7% vs. 6.9%, respectively, p<0.05). Overall, the trial data 
confirm that dabigatran is as effective as warfarin and superior to placebo for 
extended use in VTE with a lower risk of major or clinically relevant bleedings 
compared to warfarin but with a higher risk compared placebo.[56] Dabigatran was 
generally well tolerated with no difference in the rate of drug discontinuation during 
its extended use compared to both warfarin and placebo. 
 
Bleeding 
 
Bleeding can be a serious complication of any OAC treatment and fear of bleeding is 
the most common reason for OAC underutilization. As discussed above dabigatran 
has shown favorable bleeding risk profile especially the 110 bid regimen.[19] 
Intracranial hemorrhage accounts for approximately 90% of deaths from warfarin-
related bleeding and administration of either dabigatran dose significantly reduce the 
risk of hemorrhagic stroke.[19, 57, 58] 
 
A review of major bleeding events in five phase III trials of dabigatran,[19, 39, 53, 
59] which included 27,419 patients showed that subjects with major bleeds on 
dabigatran were older, had worse renal function and were more likely to be taking 
aspirin or non-steroid anti-inflammatory agents.[60] In this analysis the 30-day 
mortality related to major bleedings tended to be lower with dabigatran than with 
warfarin (9.1% vs. 13.0%; pooled odds ratio 0.68; 95% CI 0.46-1.01; p=0.057).  
Patients who developed bleeding during dabigatran treatment required shorter 
intensive care support compared with those on warfarin.[60] Management of bleeding 
events in patients receiving dabigatran is supportive.[61] Thrombin clotting time and 
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ecarin clotting time can be used to assess anticoagulation status but INR should not be 
used for this purpose.[62, 63] Activated and non-activated prothrombin complex 
concentrate and recombinant factor VIIa can be used to enhance haemostasis.[64-66] 
Low-dose FEIBA (Baxter AG, Vienna, Austria) has been reported to correct 
laboratory measures of anticoagulant effect in patients treated with dabigatran.[67] 
Idarucizumab, a humanized antibody fragment (Fab) has been developed as a specific 
antidote for dabigatran in patients with uncontrolled bleeding or requiring emergency 
intervention (see below). 
 
Periprocedural management of dabigatran 
 
A quarter of the RE-LY patients had undergone invasive procedures during 2 years of 
follow up, with the most common reasons being diagnostic and dental procedures and 
insertion of implantable devices. Periprocedural bleeding rates were similar in 
patients receiving either dabigatran dose or warfarin (3.8% with dabigatran 110 mg, 
5.1% with dabigatran 150 mg and 4.6% with warfarin). No significant difference in 
bleeding rates was seen in participants treated by dabigatran or warfarin who required 
urgent surgery, although bleeding complications were more frequent in all groups 
(17.8% with dabigatran 110 mg, 17.7% with dabigatran 150 mg, and 21.6% with 
warfarin).  
 
Dabigatran simplifies perioperative management of OAC due to its prompt offset and 
onset of action, short half-life, more predictable pharmacodynamic and 
pharmacokinetic characteristics and less drug interactions compared to warfarin. 
Consequently dabigatran allows a shorter interruption of OAC compared to warfarin 
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and thus shorter expose to increased risk of stroke.[68] The risk of major 
periprocedural bleeding with dabigatran as with any OAC depends on the type of 
procedure. Procedures with low risk of bleeding, such as gastric endoscopy, 
superficial skin surgery, including skin biopsies, minor dental procedures or wound 
revisions do not require interruption in dabigatran treatment. Minimal risk procedures 
should be performed at trough concentration, whilst avoiding the peak concentrations 
around 2 hours after ingestion.[69] Elective cardioversion is safe in subjects receiving 
dabigatran for 3 weeks prior the procedure and it should be given for at least 4 weeks 
post procedure (usually lifelong).[70, 71] 
 
Minor elective procedures, such as pacemaker insertion, coronary and other 
transluminal interventions, pleural and peritoneal puncture, eye surgery, endoscopy, 
laparoscopy, organ biopsies and dental extraction are often performed after omitting 
dabigatran for 24 hours before the procedure.[72] It has been shown to be safe to 
continue dabigatran during cardiac ablation procedures although more data are needed 
in this regard.[73] However, a recent meta-analysis suggested that periprocedural risk 
of stroke or transient ischemic attacks could be higher with dabigatran compared to 
warfarin (odds ration [OR] 3.94, 95% CI 1.54-10.08).[74] More data are essential to 
draw robust conclusions in this regard. 
 
Major procedures such as open abdominal, thoracic, brain, vascular, orthopedic or 
trauma surgery that are associated with high bleeding risk may require a longer 
dabigatran interruption.[72] Perioperative management of dabigatran does not usually 
require bridging therapy with heparin or low molecular weight heparin. However the 
balance of risks of stroke and bleeding needs to be considered on individual basis. 
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Dabigatran can be restarted as soon as effective hemostasis has been achieved after 
surgery. More prolonged interruption of dabigatran may be needed in patients with 
compromised kidney function, due to renal elimination of the drugs.[69] In patients 
receiving dabigatran major surgery should be postponed if possible to allow the drug 
elimination.[75] Dabigatran plasma levels can provide some help in estimation of 
periprocedural bleeding risk. Working Group on Perioperative Haemostasis (GIHP) 
proposed a cut-off concentration of 30 ng/ml, with surgery deemed safe with plasma 
levels below this threshold.[64]  
 
Net clinical benefit 
Clinical utility of dabigatran for stroke prevention in AF is supported by net clinical 
benefit analyses. In the population of the RE-LY trial both dabigatran doses decreased 
ischemic stroke equivalents: by 0.92 per 100 patient years (95% CI 1.74-0.21) with 
dabigatran 110 mg bid and by 1.08 (95% CI 1.86-0.34) with dabigatran 150 mg 
bid.[76]  
 
At present no data are available on direct comparisons of net clinical benefits between 
different non-VKA OAC. However in a stepwise, fixed-effects meta-analysis of bid 
vs. once daily regimens in Phase III trials showed significant advantage of dabigatran 
150 mg bid dose for stroke and systemic embolism prevention compared to once daily 
regimes used for rivaroxaban and edoxaban (HR 0.75, 95% CI 0.58-0.96).[77] One 
may speculate that the higher dabigatran dose could be considered a treatment of 
choice in patients with high risk of stroke, although direct evidence supporting the 
approach is to be obtained yet. 
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Real-World Evidence 
 
Medicare FDA Data 
Completion of the phase III clinical trials of dabigatran in non-valvular AF and its 
clinical approval was followed by assessment of efficacy and safety of dabigatran in 
settings of general practice. The Medicare FDA database that included information on 
134,  414 AF patients was used to form a propensity score-matched cohort of elderly 
individuals (75 years and above) treated with dabigatran or warfarin.[78] The analysis 
showed that treatment with dabigatran was associated with lower rates of ischemic 
stroke (HR 0.80, 95% CI 0.67-0.96); intracranial hemorrhage (HR 0.34, 95% CI 0.26-
0.46); and death (HR 0.86, 95% CI 0.77-0.96), but higher risk of major 
gastrointestinal bleeding (HR 1.28, 95% CI 1.14-1.44). These associations were most 
prominent in patients receiving the 150 mg dabigatran dose. Similar rates of 
myocardial infarction were noted with both treatments (HR 0.92, 95% CI 0.78-1.08). 
Of interest, the analysis included a significant proportion of patients treated with 
reduced 75 mg bid dabigatran dose despite the fact that most of those patients did not 
have severe renal impairment.[78] This likely reflects overall misperception of high 
risk of bleeding related to use of oral anticoagulation and temptation to reduce the 
perceived risk of bleeding by use of the lower dose of 75 mg bid of the drug despite 
the fact that they have never been tested in clinical trials. 
 
Harvard Study 
The Harvard group used US health care utilization data to assess incidence of stroke 
and bleeding events in patients newly started on warfarin or dabigatran. Groups of 
2,991 users were formed for each drug using propensity score matching. The analysis 
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did not find significant difference in stroke (HR 1.05, 95% CI 0.64-1.70) or major 
bleeding (HR 0.97, 95% CI 0.69-1.36) between the two anticoagulants. The analysis 
is limited by relatively short follow up of 1,237 person-years with dabigatran and 950 
person-years with warfarin.[79] A pooled analysis of two major US health insurance 
databases that included 19,189 propensity score matched dabigatran initiators 
indicated reduction in major hemorrhage in dabigatran users (HR 0.75, 95% CI 0.65-
0.87 based) with a trend towards less strokes in these patients (HR 0.77, 95% CI 0.54-
1.09). There was no heterogeneity of outcome in various patient subgroups, but the 
analysis is limited by the short duration of follow up (5 months for dabigatran and 4 
months for warfarin) and small event numbers.[80] 
 
Department of Defense analysis 
The US Department of Defense Military Health System database provided 
information on 12,793 propensity matched patients for each dabigatran and warfarin 
with a longer follow up (average of 297 days in the dabigatran group and 215 days in 
the warfarin group). The dabigatran patients had a higher probability of event-free 
survival (adjusted HR 0.73, 95% CI 0.55-0.97 for strokes, HR 0.49, 95% CI 0.30-0.79 
for major intracranial bleeding, HR 0.65, 95% CI 0.45-0.95 for myocardial infarction 
and HR 0.64, 95% CI 0.55–0.74 for death) with a non-significant trend towards 
higher rates of major bleeding.[81] 
 
GLORIA-AF Registry 
GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in 
Patients with Atrial Fibrillation) is a large multinational registry program setup to 
establish factors that influence choice of stroke prevention strategies in patients with 
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non-valvular AF (CHA2DS2-VASc score ≥1). The program aims to enrol up to 56,000 
patients in nearly 50 countries and it includes 3 phases: Phase I, before the 
introduction of novel OACs, Phase II, after the introduction of dabigatran into 
practice; and Phase III, analysis of large treatment groups, subjected for propensity 
score matching to account for demographic and clinical differences in real-world 
data.[82, 83] 
 
In Phase I 1063 patients were enrolled, 67.1% in Asia, 27.4% in Europe and 5.6% in 
Middle East. The analysis showed noticeable regional differences in utilization of oral 
anticoagulation. For example, the majority of patients in China received antiplatelet 
agents (53.7%) with about 2-fold lower rates of aspirin utilization in other regions. In 
contrast, in the EU almost 64% of patients were treated with VKAs. VKAs were used 
in about 30% of Middle East patients.[84] Initial Phase II data emerged from North 
America where dabigatran had earlier approval for clinical use. In 1672 North 
American AF patients 76.4% received oral anticoagulation (including dabigatran in 
32.1% and VKA in 29.2%), whilst almost half of patients in China had no or 
inadequate antithrombotic therapy. Overall, patients started on dabigatran and VKAs 
had similar baseline stroke and bleeding risk, but patients prescribed dabigatran were 
older and included more subjects with kidney dysfunction, diabetes, and congestive 
heart failure.[85] Further data from the GLORIA program are awaited with interest. 
 
Danish Registry 
Propensity matched analysis of the Danish Registry of Medicinal Product Statistics 
involving 4978 patients receiving dabigatran and 8936 patients treated with warfarin 
showed similar rates of stroke and systemic embolism with the two treatments. 
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However treatment with dabigatran was associated with lower mortality (adjusted HR 
0.79, 95% CI 0.65-0.95 for 110 mg dose and adjusted HR 0.57, 95% CI 0.40-0.80 for 
150 mg dose). Patients receiving either dose of dabigatran were also at lower risk of 
pulmonary embolism, intracranial bleeding, and myocardial infarction. Furthermore, 
use of 110 mg dose of dabigatran was associated with lower risk of gastrointestinal 
bleeding compared to warfarin. These data indicate that in everyday practice 
dabigatran could bring more clinical benefits compared to warfarin than it could be 
expected based on clinical trials, perhaps do to suboptimal INR control in some 
patients receiving warfarin.[86] 
Real world data confirm efficacy and safety of dabigatran in older people 
In a population-level analysis from the North America, based on a cohort of 15,918 
AF patients on dabigatran and 47,192 matched patients receiving warfarin 67% of 
patients were 75 years or older.[58] In the elderly group dabigatran showed the same 
effectiveness for stroke prevention as warfarin (HR 1.05, 95% CI 0.93-1.19) for both 
dabigatran doses, but dabigatran was linked with less intracranial bleeding (HR 0.60, 
95% CI 0.47-0.76) and more gastrointestinal hemorrhages (HR 1.30 95% CI 1.14-
1.50). The 2014 UK NICE guidelines on AF list 110 mg dabigatran dose as an 
alternative to warfarin in people 75 years or older.[87]  
 
Mechanical heart valves 
 
Despite its remarkable success in revolutionising oral anticoagulation in non-valvular 
AF and VTE management, dabigatran was not successful in the management of some 
prothrombotic conditions. The phase 2 randomised RE-ALIGN trial tested the utility 
of the drug started 4-7 days after mechanical aortic- or mitral-valve replacement, or in 
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patients who had undergone mechanical valve replacement at least three months 
earlier.[88] Dabigatran was started at 150, 220 or 300 mg bd dose depending on renal 
function and further corrected to maintain trough plasma level of 50 ng/mL or higher. 
Warfarin served as a comparator. The study was terminated early due to increased 
rates of thromboembolic and bleeding complications in the dabigatran arm. The 
results likely reflect inability of the drug to block coagulation activation stimulated by 
exposure of the blood to mechanical heart valves, particularly in the early post-
operative period when blood levels of the drug were lower. 
 
 
Outlook 
 
New Studies 
Several new studies aim to complete important gaps in knowledge on possible utility 
of dabigatran. Embolic strokes of undetermined source (a subgroup of cryptogenic 
strokes) represent 20-25% of all ischemic strokes and often related to ‘silent’ AF. The 
ongoing RESPECT-ESUS study is an phase III, double-blind, randomized clinical 
trial that compares 150 mg bid or 110 mg bid dabigatran with 100 mg once daily 
aspirin for secondary stroke prevention in patients with embolic stroke of 
undetermined source in 6000 patients over observation period of 0.5-3 years.[89] 
 
The RE-CIRCUIT (Randomized Evaluation of dabigatran etexilate Compared to 
warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural 
anticoagulation strategy) trial aims to determine utility of dabigatran (150 mg bid) 
treatment during cardiac ablation procedures compared with warfarin in over 700 
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patients with paroxysmal or persistent AF. The study will compliment available 
observational studies, and meta-analyses.[90] 
 
The RE-DUAL PCI (Randomized Evaluation of Dual Therapy with Dabigatran vs. 
Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone 
PCI with Stenting) non-inferiority trial compares combination of dabigatran (110 mg 
bid or 150 mg bid) plus clopidogrel or ticagrelor with a triple antithrombotic therapy 
of warfarin plus clopidogrel or ticagrelor plus aspirin in patients AF undergoing 
percutaneous coronary intervention.  
 
A further phase IV study is expected to assess dabigatran for the treatment of VTE in 
the real world.[91] RE-COVERY is a prospective cohort non-interventional study of 
dabigatran for the management of VTE. The study is aimed to characterize patients 
with DVT or PE, to evaluate therapeutic strategies, and to assess the safety and 
effectiveness of dabigatran versus VKAs in routine care.[92] 
 
Idarucizumab 
Dabigatran has a favorable predictable pharmacokinetic profile with reasonably low 
risk of bleeding complications. However a number of clinical situations would still 
require prompt reversal of the drug activity. Those situations could be related to 
serious and life-threatening bleeding events (e.g. intracerebral bleeding), cases of drug 
overdose and emergency surgery.  
 
A specific humanized Fab, idarucizumab, was developed as a reversal agent for 
dabigatran. The antibody binds dabigatran with high affinity and prevents inhibition 
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of thrombin by dabigatran. Idarucizumab was initially tested in pig blunt liver trauma 
model where animals not receiving idarucizumab consistently died from bleeding.[93] 
Treatment with idarucizumab led to dose-dependent reduction in blood loss with only 
17% mortality and 50% reduction in blood loss seen even with the lowest tested 
idarucizumab dose (30 mg/kg). Higher, 60 or 120 mg/kg idarucizumab doses were 
associated with 100% survival of the treated animals. 
 
In a randomized, double-blind, placebo controlled study of 145 healthy volunteers all 
tested doses of idarucizumab (up to 8 g) were well tolerated and safe and the agent 
provided immediate, complete and sustained reversal of dabigatran induced 
anticoagulation.[94] It has been further shown that 5 g of idarucizumab provides fast 
complete reversal of dabigatran induced anticoagulation in mid-aged and elderly 
healthy individuals and patients with kidney dysfunction.[95] Moreover, further oral 
intake of dabigatran 24 hours after administration of idarucizumab restored adequate 
anticoagulation. In all available reports idarucizumab was well tolerated and its 
availability would provide further confidence for clinicians and safety for patients. 
[96] 
 
An analysis of the first 90 patients enrolled in the ongoing, multicenter, prospective 
cohort Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD) trial 
included 51 patients with overt, uncontrollable, or life-threatening bleeding (mostly 
intracranial or gastrointestinal hemorrhage) and 39 patients in need for emergency 
invasive procedures, which required normal hemostasis.[97] Over 90% of the 
participants were treated with dabigatran for stroke prevention in view of AF. The 
primary end point was reversal of the anticoagulant effect of dabigatran within 4 
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hours of completion of the drug infusion as tested by the dilute thrombin time or 
ecarin clotting time. Intravenous administration of 5 g of idarucizumab rapidly and 
completely reversed the anticoagulant effect of dabigatran in 88-98% of the patients 
with prolonged clotting times. In patients who underwent an intervention, normal 
hemostasis was achieved in 92% with mild-to-moderate hemostasis impairment 
reported in 8%. There were 5 thrombotic events recorded at the time of the analysis, 
all of which occurred off anticoagulants. Idarucizumab has been approved in the US 
for uncontrollable or life-threatening bleeding and/or in need for emergency invasive 
procedures of surgery.[98] Approval of the agent in the EU was also granted.[99] 
 
Overall perspectives 
In view of significant pharmacokinetic and pharmacodynamic limitations of warfarin 
introduction of non-VKA oral anticoagulants was awaited with great interest. With 
growing evidence of efficacy and safety of dabigatran for several indications, together 
with its ease of use and expected to reduce costs, the drug along with other non-VKA 
oral anticoagulants are becoming the first-line option for most indications for oral 
anticoagulation. Until further development warfarin will remain the treatment of 
choice for patients with advanced renal disease and management of mechanical 
prosthetic valves. Currently, there are no robust data to suggest the superiority of one 
non-VKA oral anticoagulant over another. However, dabigatran benefits from the 
longest record of clinical use and the availability of a specific reversal agent. 
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Conclusion 
 
Dabigatran is an oral direct thrombin inhibitor that can be used with fixed doses and 
no need for routine monitoring. The drug benefits from few inter-drug interactions. 
Dabigatran is effective for the prevention of stroke and systemic thromboembolism in 
AF and for management of VTE. The agent has excellent safety profile with no 
evidence of liver toxicity and clear reduction in intracranial hemorrhage risk 
compared to warfarin. A specific reversal agent for dabigatran has been approved by 
FDA in the US, Committee for Medicinal Products for Human use (CHMP) of the 
European Medicines Agency (EMA) in the EU and Health Canada in Canada.  
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Table 1. Pharmacological characteristics 
 Dabigatran Warfarin 
Target Factor II (thrombin) Vitamin K dependent factors: 
II, VII, IX and X 
Bioavailability 6.5% >95% 
Peak concentrations 1-2 h 0.3 to 4 h 
Half life 14-17 h 35-45 h 
Protein binding 35% >98% 
Renal excretion 80% 0% 
Potential interactions P-gp inhibitors, potent P-gp 
inducers 
Inhibitors of CYP2C9, 3A4, 
1A2 
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Table 2. Randomized clinical trials of dabigatran in major joint surgery 
 Duration of 
treatment 
Initiation of 
dabigatran 
post operation 
VTE and all-cause mortality (%) 
Dabigatran 
150 mg od 
Dabigatran 
220 mg od 
Enoxaparin 
 
Total heap replacement 
RE-NOVATE 
(n=3494) 
6-10 days 1-4 h (with 
half dose) 
6.7 
 
8.6 
 
6.0† 
Total knee replacement 
RE-MODEL 
(n=2076) 
6-10 days 1-4 h (with 
half dose) 
37.7 40.5 36.4† 
RE-MOBILIZE 
(n=1896) 
12-15 days 6-12 hours 
post 
operation 
25.3* 33.7* 31.1‡ 
*Inferior to enoxaparin, †40 mg s.c. once daily, ‡ 30 mg s.c. twice daily. od, once daily.  
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Table 3. Randomized clinical trials of dabigatran 150 mg bid in venous thromboembolism 
Study   Number Comparator  
Treatment 
Recurrent VTE 
HR (95% CI) 
All death  
HR (95% CI) 
Major bleeding 
HR (95% CI) 
Any bleeding 
HR (95% CI) 
Long-term treatment of acute VTE 
RE-COVER [39]  2539 Warfarin 1.10 (0.65-1.84) 0.98 (0.53-1.79) 0.82 (0.45-1.48) 0.71 (0.59-0.85)* 
RE-COVER II[40] 2589 Warfarin 1.08 (0.64-1.80) 0.98 (0.56-1.71) 0.69 (0.36-1.32) 0.67 (0.56-0.81)‡  
Pooled RE-COVER and 
RE-COVERII
[40]
 
2539+2589 Warfarin  1.09 (0.76-1.57) 1.0 (0.67-1.51) 0.73 (0.48-1.11) 0.70 (0.61-0.79)‡ 
Extended treatment for prevention of VTE recurrence 
RE-MEDY
[53]
 2856 Warfarin 1.44 (0.78-2.64)  0.90 (0.47-1.72)  0.52 (0.27-1.02) 0.71 (0.61-0.83)*  
RE-SONATE
[53]
 1343 Placebo 0.08 (0.02-0.25)*   Not estimable 1.82 (1.23-2.68)† 
*p<0.001; †p≤0.01; ‡p<0.05; bid, twice daily; CI, confidence interval; HR, hazard ratio; VTE, venous thromboembolism;  
RE-COVER and RE-COVER II - treatment for 6 months, with prior intravenous heparin or subcutaneous low molecular weight heparin for a 
median of 9 days. RE-MEDY- treatment for median of 16 months (6 to 36 months) with prior anticoagulation at least for 3 months.  
RE-SONATE – treatment for 6 months with prior anticoagulation at least for 3 months. 
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Figures legends: 
Figure 1. Substudies of the RE-LY trial on effectiveness of dabigatran 110 mg vs warfarin for 
prevention of stroke and systemic embolism 
*Results for VKA, previous stroke/TIA, cardioversion and patients from Japan presented as relative risk 
(95% CI); bid, twice daily; CI, confidence interval; INR, international normalised ratio; TIA, transient 
ischaemic attack; TTR, time in therapeutic range; VKA, Vitamin K antagonist. Eikelboom et al. 
(2011)[25]; Nagarakanti et al. (2013) [100]; Ferreira et al. (2013)[101]; Hijazi et al. (2014)[24]; Oldgren 
et al. (2011)[26]; Dans et al. (2013)[102]; Hori et al. (2013)[103]; Ezekowitz et al. (2010)[104]; 
Wallentin et al. (2010)[105]; Diener et al. (2010)[106]; Nagarakanti et al. (2011)[70]; Hori et al. 
(2011)[107]. 
 
Figure 2. Substudies of the RE-LY trial on effectiveness of dabigatran 150 mg vs warfarin for 
stroke and systemic embolism prevention  
*Results for VKA, previous stroke/TIA, cardioversion and patients from Japan presented as relative risk 
(95% CI); bid, twice daily; CI, confidence interval; INR, international normalised ratio; TIA, transient 
ischaemic attack; TTR, time in therapeutic range; VKA, Vitamin K antagonist. Eikelboom et al. 
(2011)[25]; Nagarakanti et al. (2013) [100]; Ferreira et al. (2013)[101]; Hijazi et al. (2014)[24]; Oldgren 
et al. (2011)[26]; Dans et al. (2013)[102]; Hori et al. (2013)[103]; Ezekowitz et al. (2010)[104]; 
Wallentin et al. (2010)[105]; Diener et al. (2010)[106]; Nagarakanti et al. (2011)[70]; Hori et al. 
(2011)[107]. 
 
Figure 3. Substudies of the RE-LY trial on risk of major bleeding with dabigatran 110 mg vs 
warfarin 
*Results for VKA, periprocedure bleeding, previous stroke/TIA, cardioversion and patients from Japan 
presented as relative risk (95% CI) bid, twice daily; CI, confidence interval; INR, international 
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normalised ratio; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, Vitamin K 
antagonist. Eikelboom et al. (2011)[25]; Nagarakanti et al. (2013) [100]; Ferreira et al. (2013)[101]; 
Hijazi et al. (2014)[24]; Oldgren et al. (2011)[26]; Dans et al. (2013)[102]; Hori et al. (2013)[103]; 
Ezekowitz et al. (2010)[104]; Wallentin et al. (2010)[105]; Healey et al. (2012)[68]; Diener et al. 
(2010)[106]; Nagarakanti et al. (2011)[70]; Hori et al. (2011)[107]. 
 
Figure 4. Substudies of the RE-LY trial on safety of dabigatran 150 mg vs warfarin on risk of 
major bleeding 
 
*Results for VKA, periprocedure bleeding, previous stroke/TIA, cardioversion and patients from Japan 
presented as relative risk (95% CI) bid, twice daily; CI, confidence interval; INR, international 
normalised ratio; TIA, transient ischaemic attack; TTR, time in therapeutic range; VKA, Vitamin K 
antagonist. Eikelboom et al. (2011)[25]; Nagarakanti et al. (2013) [100]; Ferreira et al. (2013)[101]; 
Hijazi et al. (2014)[24]; Oldgren et al. (2011)[26]; Dans et al. (2013)[102]; Hori et al. (2013)[103]; 
Ezekowitz et al. (2010)[104]; Wallentin et al. (2010)[105]; Healey et al. (2012)[68]; Diener et al. 
(2010)[106]; Nagarakanti et al. (2011)[70]; Hori et al. (2011)[107] 
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Figure 4  
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Highlights 
 Dabigatran is a direct thrombin inhibitor used with fixed doses.  
 The drug is effective for stroke prevention in atrial fibrillation.  
 Dabigatran used for the management of venous thromboembolism.  
 Dabigatran shows a reduction in intracranial haemorrhage risk compared to warfarin. 
 A specific reversal agent for dabigatran has been approved by FDA and EU.  
